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The precise mechanism of vasodilatory actions of ni-
troso-compounds is not clear. It has been suggested that
these drugs might modulate release of the vasodilator,
prostacyclin, from cultured endothelial cells and bovine
arteries or potentiate actions of prostacyclin. This study
was designed to examine the effects of nitroglycerin and
nitroprusside on prostacyclin release from adult human
vasculature. Saphenous vein ring preparations were in-
cubated with nitroglycerin or nitroprusside and arach-
idonicacid, the substrate for prostacyclin. Vascular rings
incubated with nitroglycerin released significantly more
prostacylin (measured as 6-keto-prostaglandin FI,,, a sta-
ble hydrolysis product of prostacyclin by radioimmu-
noassay) compared with the control vascular rings (p <
0.02). This increase was observed at the therapeutic con-
centrations of nitroglycerin (5 to 10 ng/ml). However,
incubation of saphenous vein rings with nitroprusside in
Nitroglycerin and nitroprusside are potent vasodilators used
in a variety of cardiovascular disorders. Nitroglycerin has
preferential venodilatory actions, whereas nitroprusside has
equipotent venodilatory and arteriodilatory actions. The pre-
cise mechanism by which these agents dilate human blood
vessels is not known, although modulation of vessel wall
cyclic nucleotides has been speculated to be a mechanism
of their action (1-3).
During the last several years, an important role of the
arachidonic acid metabolites, thromboxane A2 and prosta-
cyclin, in the pathogenesis of increased vascular resistance
has been implicated (4-7). Thromboxane A2 , generated pri-
marily by the platelets, is a potent vasoconstrictor and plate-
let proaggregant, whereas prostacyclin produced by the blood
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concentrations as high as I Itg/ml was not associated
with any increase in prostacyclin release.
Prior incubation of vascular rings with the cyclo-
oxygenase blocker, indomethacin, inhibited nitrogly-
cerin-induced prostacyclin release. Incubation of vas-
cular rings with the selective thromboxane A2 blocker,
OKY 1581, resulted in additional prostacyclin release
with nitroglycerin treatment, presumably by inhibiting
vessel wall-generatedthromboxane A2• Nitroprusside had
no significant effect on prostacyclin release from indo-
methacin-treated or OKY 1581-treated vascular rings.
This study suggests significant stimulatory effects of
nitroglycerin, but not of nitroprusside, on prostacyclin
release from human saphenous vein. Nitroglycerin-in-
duced prostacyclin release may be an important mech-
anism of its antiischemic actions in human subjects.
vessels is a potent vasodilator and platelet antiaggregant.
An imbalance between these two major prostaglandins to-
ward thromboxane A2 or away from prostacyclin may be a
cause of increased vascular resistance. Indeed, increased
thromboxane A2 synthesis and decreased prostacyclin gen-
eration have been identified in ischemic heart disease (6,8,9).
Enhanced in vivo platelet activity has been observed in
congestive heart failure (10) and hypertension (11,12). Ni-
troglycerin (13), but not nitroprusside (14), has been shown
to stimulate prostacyclin synthesis by cultured umbilical
vein endothelial cells.
Because vascular prostacyclin generation decreases with
age (15,16), it is important to examine the effect of these
agents on blood vessels obtained from adult patients who
may receive these drugs. In previous studies, cultured cells
after several passages were used, which mayor may not
indicate prostacyclin production by adult human vasculature
in response to these agents. The present studies were per-
formed to examine the production of prostacyclin by adult
human vascular tissues in response to nitroglycerin and
nitroprusside.
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Methods
Preparation of vascular tissues for prostacyclin gen-
eration. The blood vessels examined were human saphe-
nous veins that were obtained from six patients (aged 55 to
62 years) undergoing coronary bypass surgery immediately
after anesthesia and leg dissection. Informed consent was
obtained from all patients, none of whom had taken pro-
staglandin-active drugs during the previous 10 days. The
tissues were collected in calcium- and magnesium-free phys-
iologic buffer (described under reagents) at 4°C. All ex-
periments were conducted within 3 hours of tissue collection.
The technique for preparation ofvascular tissue has been
previously described (17,18). In brief, the saphenous veins
were gently dissected free from the surrounding tissue and
cut into fine rings (0.5 to 1 mm thickness). Aliquots of
vascular rings (wet weight 30 to 35 mg) were placed into
small polypropylene vials containing 1 ml of calcium- and
magnesium-free buffer. The rings were gently washed sev-
eral times with buffer, and placed in 1 ml of Hanks buffered
salt solution (HBSS, referred to as "buffer") containing
calcium and magnesium for 15 minutes. The aliquots were
then incubated with nitroglycerin or nitroprusside (5, 10,
100 and 1,000 ng/ml, final concentration) in buffer at 37°C
for 15 minutes, followed by treatment with arachidonic acid
(0.1 mM) for an additional 15 minutes.
In each experiment, the following control incubations of
vascular rings were performed: buffer alone without nitro-
glycerin or nitroprusside, and buffer plus lactose or saline
solution (vehicles for nitroglycerin or nitroprusside, re-
spectively). In other experiments, vascular rings were first
treated with the cyclo-oxygenase inhibitor, indomethacin,
0.1 mM, for 15 minutes before incubation with nitroglycerin
or nitroprusside and then with arachidonic acid. Previous
studies have indicated generation of thromboxane A2 in
addition to prostacyclin by human saphenous veins (17),
and have shown that selective thromboxane A2 inhibition
may divert arachidonic acid metabolism to prostacyclin (19).
Therefore, in some experiments, vascular rings were treated
with a selective thromboxane A2inhibitor, OKY 1581 (20),
0.1 mM, for 15 minutes before incubation with nitroglycerin
or nitroprusside plus arachidonic acid.
6-keto-PGFla determination. 6-keto-prostaglandin F1m
a stable hydrolysis product of prostacyclin, was measured
by radioimmunoassay (17). Lyophilized standards, anti-
bodies and 3H 6-keto-PGF1a were obtained from New Eng-
land Nuclear Corporation. The crossreactivity of 6-keto-
PGF 1a antibody was 100% for6-keto-PGF 1a , 2.7% for pros-
taglandin F2m less than 2% for prostaglandin E2, and less
than 0.1 % for prostaglandin A2 and thromboxane B2 (21).
All measurements in the supemates were made in duplicate
and results expressed as pg/mg tissue wet weight. The du-
plicate 6-keto-PGF1a values varied by 10%.
Reagents. Calcium- and magnesium-free buffer was
prepared according to Jaffe et al. (22). Buffer consisted of
138 mM sodium chloride (NaCl), 4 mM potassium chloride
(KCl), 0.5 mM sodium phosphate dibasic (Na2HP04), 0.15
mM potassium phosphate monobasic (KH2P0 4), 11.7 mM
chloride dextrose and final pH 7.4. Calcium- and magne-
sium-containing buffer contained 1.3 mM calcium chloride
dehydrase, (CaCL2 . 2H20) , 5.4 mM KCI, 0.4 mM KH2
P04, 0.8 mM magnesium sulfate (MgS04 . 7 H20), 136.9
mM NaCl, 4.2 mM sodium bicarbonate (NaHC03), 0.3 mM
Na2HP04, 5.6 mM dextrose adjusted to pH 7.4 with 1 N
sodium hydroxide (NaOH). Indomethacin (Merck, Sharp,
and Dohme) was dissolved in Tyrode solution (final pH 7.4)
with gentle boiling. The selective thromboxane A2 synthe-
tase inhibitor, OKY 1581 (Ono Pharmaceutical Co., Ltd.)
(20) was kept at - 70°C until use and was dissolved in a
normal saline solution just before use. Arachidonic acid
(Sigma Chemical Co.) was kept at -70°C until use, dis-
solved in Tris buffer and kept under nitrogen before use
(final pH 7.4). Nitroglycerin in lactose (Eli Lilly and Co.)
was diluted with normal saline solution. Crystalline nitro-
prusside (Hoffmann La Roche) was dissolved in normal
saline solution and was protected from light by covering the
solution with aluminum foil.
Statistical calculations. All data were obtained from at
least five experiments. All measurements were made in du-
plicate and averaged. The average values were used to cal-
culate the mean ± standard error. The Student's t test (paired
data) and multiple analysis of variance were used for sta-
tistical calculations. A probability (p) value less than 0.05
was considered significant.
Results
Effect of nitroglycerin on prostacyclin production.
After multiple washings and incubation of saphenous vein
rings with buffer alone, the measurement of 6-keto-PGF1a
revealed concentrations in the supemates varying from 48
to 116 pg/mg (mean 72 ± 10; n = 6). Concentrations of
6-keto-PGF1a in the supemates of different aliquots of vas-
cular rings from the same saphenous vein varied by 9%
(range 6 to 12).
Concentrations of 6-keto-PGF1a in the supemates after
incubation with buffer plus arachidonic acid varied from
108 to 612 pg/mg (mean 260 ± 45; p < 0.01 compared
with buffer alone; n = 6). Treatment of vascular rings with
lactose (vehicle for nitroglycerin) and then with arachidonic
acid for 15 minutes did not significantly affect 6-keto-PGF1a
levels (mean 275 ± 51 pg/mg; n = 6). Vascular rings
treated with nitroglycerin released significantly more (p <
0.01) 6-keto-PGF1a on treatment with arachidonic acid than
did those not treated with nitroglycerin (Fig. 1). An increase
in 6-keto-PGF1a was present in all supemates of vascular
rings treated with nitroglycerin. Maximal increase was ob-
served at 5 ng/ml in one experiment (mean increase 17%;
n = 5), at 10 ng/ml in two experiments (mean increase
28%; n = 5), at 100 ng/ml in two experiments (mean
increase 40%; n = 6) and at 1,000 ng/ml in one experiment
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(mean increase 32%; n = 5). At 5 to 10 ng/ml concentra-
tions of nitroglycerin , 6-keto-PGFl a levels increased sig-
nificantly (p < 0.02) comparedwith thecontrol(bufferalone
or bufferplus lactose). There weresmall additionalincreases
when higher concentrations of nitroglycerin were used.
In experiments in which vascular rings were first treated
with indomethacin. arachidonic acid-stimulated 6-keto-PGF'a
levels were significantly lower ( - 54 ± 7%; p < 0.01) than
those from the vascular rings not treated with indomethacin
(Table I). Incubation with nitroglycerin and arachidonic
acid of indomethacin-treated vascular rings failed to stim-
ulate prostacyclin release. Incubation of OKY 1581-treated
vascular rings with arachidonic acid resulted in 6-keto-PGF,u
concentrations in supernates significantly higher (+ 26 ±
5%; p < 0.02) than those from the rings not treated with
OKY 1581. Nitroglycerin treatment resulted in significantly
higher concentrations (p < 0.05) of 6-keto-PGF'a in the
supernates of vascular rings treated with OKY 1581 (Fig.
1). This was observed at 5 and IO ng/ml concentrations of
nitroglycerin (Table I).
Effect of nitroprusside on prostacyclin production.
Before incubation with arachidonic acid, supernates of vas-
cular rings (not treated with nitroprusside) contained 48 to
194 pg/mg (mean 90 ± 16) of 6-keto-PGFt a (n = 5). On
incubation of vascular rings with arachidonic acid, the con-
centrationof 6-keto-PGF,u increased in each supernatecom-
pared with those incubated in buffer alone (range 150 to
366; mean 241 ± 36 pg/rng; p < 0.01). However, 6-keto-
PGF\u concentrations in the supernates of all vascular rings
were similar, whether or not they had been treated with
nitroprusside (Fig. 2).
In experiments in which vascular rings were first treated
with indomethacin. arachidonic acid-stimulated 6-keto-PGFIu
concentrations were significantly lower ( - 46 ± 12%; p <
0.02) than those from the vascular rings not treated with
indomethacin. Incubation with nitroprusside and arachi-
donic acid of indomethacin-treated vascular rings failed to
stimulate prostacyclin release (Table I). In contrast, vas-
cular rings treated with OKY 1581 produced more prosta-
cyclin ( + 24 ± 9%; p < 0.05) after treatment with arach-
idonic acid than did those not treated with OKY 1581.
Nonetheless, nitroprusside treatment in any concentration
failed to significantly affect 6-keto-PGFtu concentrations.
Figure 1. Effect of nitroglycerin (NTG) on prostacychn (PGIz)
release from the adult human saphenous vein rings. Nitroglycerin
significantly increased (p < 0.02) 6-keto-prostaglandin F l a (POF l a )
concentrations in the supernates at 5 to 10 ng/ml concentrations.
Indomethacin (INDO ) reduced, whereas OK Y 1581 enhanced 6-
keto-PGFI " concentrations. Nitroglycerin had no effect on PGIz
release from indomethacin-treated vascular rings, but enhanced
PGh release from OKY 1581 -treated vascular rings. All ahquots
of vascular rings were treated witharachidonic acid. Controlvalues
for nitroglycerin (0 ng /rnl) refer to arachidonic acid In buffer plus
lactose.The data arc a summaryof six separateexperiments; values
are expressed as mean ± standard error of the mean.
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Discussion
Effect of nitroglycerin on prostacyclin release . This
study demonstrates that nitroglycerin stimulates prostacyclin
release from human saphenous vein rings. This increase
occurs in clinically achieved concentrations of 5 to 10 ng/
ml (23). Stimulation of vascular prostacyclin release in re-
sponse to nitroglycerin treatment is supported by the mea-
surements of 6-keto-prostaglandin FI " (PGFIu) in the vas-
cular ring supernates. Pretreatmentof the vascularrings with
indomethacin inhibited prostacyclin release, whereas pre-
treatment with OKY 1581 stimulated prostacyclin in re-
sponse to nitroglycerin. In contrast, nitroprusside had no
significant effect on prostacyclin release from the saphenous
vein rings. In addition, nitroprusside had no stimulatory
effect on prostacyclin release even when vascular rings had
been pretreated with OKY 158 1.
It is evident that prostacyclin measured as 6-keto-PGFj o
was indeed releasedfrom the vascular rings. Indomethacin,
by blocking cyclo-oxygenase enzyme, prevented the syn-
thesis of prostacyclin. Nitroglycerin or nitroprusside treat-
ment followed by incubation with arachidonic acid failed
to stimulate prostacyclin (Table I). Treatment with OKY
1581 , a selective thromboxane A2 synthetase inhibitor (20),
resulted in an increase in prostacyclin release. It is known
that human saphenous veins also synthesize thromboxane
Az in addition to prostacyclin (17) and that selective throm-
boxane Az inhibition may divert cyclic endoperoxides to-
ward prostacyclin (7,19). In this study, we did not measure
thromboxane B2 levels in the supernates, but the use of
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Table l. Effect of Prostaglandin Inhibitors On Prostacyclin (PGI2) Release
Vascular rings + buffer + AA
Vascular rings + NTGor NP + AA
Vascular rings + indomethacin + AA
Vascular rings + indomethacin + NTGor NP + AA
Vascular rings + OKY 1581 + AA
Vascular rings + OKY 1581 + NTGor NP + AA
NTG Experiments
(n=6)
260 ± 45
333 ± 50§
120 ± 25+
125 ± 30
328 ± 49t
410 ± 45*
6-keto-PGFI..(pg/mg)
NP Experi ments
(n=5)
24 1 ± 36
245 ± 45
130 ± 29+
139 ± 25
300 ± 38t
310 ± 40
Data refer to experiments with 10 ng/ml of nitroglycerin or nitroprusside.
* p < 0.02 compared with OKY 1581 + AA; t P < 0.02 compared with buffer + AA; +P < 0.01 compared with buffer + AA; § P < 0.01
compared with buffer + AA.
AA = arachidonic acid; buffer = Hanks buffered salt solution; NP = nitroprusside, 10 ng/rnl, NTG = ni troglycerin, 10 nglm l.
OKY 1581 increased 6-keto-PGF l o levels, probably by in-
hibiting thrombo xane A2 synthesis.
Methodologic considerations. As in several previous
studies (17,18,24-26), we employed vascular rings that in-
cluded all layers of the vessel wall, in contrast to cultured
Figure 2. Effect of nitroprusside (NP) on prostacyclin (PGh) re-
lease from the saphenous vein rings . Nitroprusside had no signif-
icant effect on 6-keto-PGF l a concentrations in the supernates in
concentrations up to 1,000 ng/m!. Indomethacin (INDO) reduced,
whereas OKY 1581 enhanced prostacyclin release. Nitroprusside
had no effect on indomethacin-treated or OKY 1581 -treated vas-
cular rings . All aliquots of vascular rings were treated with ar-
achidonic acid. Control data for nitroprusside (0 ng/ml ) refer to
arachidonic acid in buffer plus normal saline solution. The data
are a summary of five separate experiments: values are expressed
as mean ± standard errorof the mean.
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endothelial cells used by others (13,14). Some major meth-
odologic differences of our experiments compared with those
of others are noteworthy. First. prostacyclin measured in
the vascular ring supernate by our method includes release
from all layers of the vessel wall. Although the precise
contribution of smooth muscle layers in the release of pros-
tacyclin (27) cannot be ascertained, it is known that the
endothelial cells generate much more prostacyclin than do
the smooth muscle cells. Therefore, it can be assumed that
the recovered prostacyclin was derived mostly from the
endothelial cells. Second, the saphenous veins were ob-
tained after anesthesia, which may influence the release of
prostaglandins. Third, trauma to the blood vessels during
preparation of vascular rings may also cause prostacyclin
release (28). However, similarly prepared rings were used
for studying the effects of nitroglycerin, nitroprusside and
multiple control agents. Because prostacyclin release was
observed only in nitroglycerin-treated rings, it is likely that
nitroglycerin alone stimulated prostacyclin release.
Previous studies employing cultured umbilical vein cells
(13) and bovine coronary arteries (29) have shown nitro-
glycerin-induced potentiation of prostacyclin release. We
employed fresh human saphenous vein rings and studied
them within 3 hours of collection to determine whether rings
fromthe entire vesselwouldbehave differently from isolated
cultured endothelial cells after two or three serial passages.
Comparison of our data with those of Levin et al. (13)shows
that the magnitude of prostacyclin stimulation by human
saphenous vein rings is the same as that by cultured endo-
thelial cells at the same concentration of nitroglycerin. In
studies by Schror et al. (29), maximal prostacyclin release
from bovine coronary artery strips occurred at 0.3 to 3 ngl
ml concentrations of nitroglycerin. Concentrations of 1 J.Lgl
ml or greater resulted in a decrease in prostacyclin release.
Our data do not suggest any decrease in prostacyclin release
with nitroglycerin up to I J.Lg/ml , although maximal stim-
ulation is observed at lower concentrations. These concen-
tration-related differences in nitroglycerin-stimulated pros-
l ACC Vol. 2. No 4
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tacyclin release may relate either to differences in canine
and human vessels or to the types of vessels used (that is.
coronary artery versus saphenous vein). Nevertheless. data
from all these studies indicate stimulation of prostacyclin
release by nitroglycerin in therapeutic concentrations. In
contrast. nitroprusside failed to stimulate prostacyclin re-
lease from human saphenous vein rings in any concentra-
tion. These data are in accord with a recent study (14) that
failed to show significant effects of nitroprusside on pros-
tacyclin release from cultured endothelial cells.
Nitroglycerin versus nitroprusside. In a previous study
(30), nitroglycerin was shown to decreasecoronary vascular
resistance accompanied by release of prostaglandins of the
E series in dogs. Both of these effects of nitroglycerin were
blockedby indomethacin . Other investigators were not able
to show any significant effects of nitroglycerin on prosta-
cyclin release using pig aortic microsomes (31), or rat or
guinea pig heart after high concentrations of nitroglycerin
(32). A recent report (33), however, shows an increase in
prostacyclin release in human coronary venous blood after
the administration of sublingual nitroglycenn. The differ-
ences in these observations may relate to several factors: I)
very high concentrations of nitroglycerin may reduce pros-
tacyclin release (29), 2) there may be specific species dif-
ferences, and 3) endothelial cells are necessary for effects
of nitroglycerin on prostacyclin release (13).
Nitroprusside has been shown to inhibit platelet adhesion
(34) . platelet aggregation and thromboxane A2 synthesis
(10,14) . It has been suggested that nitroprusside may act
by inhibiting platelet function . In studies in patients with
congestive heart failure. nitroprusside reduced both ex vivo
and in vivo platelet aggregation (10,35), but nitroglycerin
had no signifi cant effect on platelet aggregation in thera-
peutic concentrations (35). Although nitroglycerin inhibits
platelet aggregation in supratherapeutic concentrations ( >
to ng/ml) (36), human platelet thromboxane A2 generation
may be decreased by small concentrations of nitroglycerin
(37). Levinet al. showed some potentiation of prostacyclin-
induced platelet aggregation inhibition by nitroglycerin (13)
and nitroprusside (14). Thus, it appears that nitroglycerin
has important prostacyclin-stimulating effects but no sig-
nificant effects on thromboxane A2 in therapeutic concen-
trations, whereas nitroprusside lacks significant effects on
prostacyclin release but has important effects on thrombox-
ane A2 generation.
Clinical implications . Nitroglycerin relieves myo-
cardial ischemia by systemic venodi1ation (38), direct local
coronary vasodilation (39,40) and redistribution of blood
flow from nonischemic to ischemic areas (41,42). An in-
crease in prostacyclin release by nitroglycerin in therapeutic
concentration may be an important mechanism of its action
in human beings. Although a potent vasodilator, nitroprus-
side does not appear to have significant effects on prosta-
cyclin release from adult human saphenous vein rings. Pros-
tacyclin has myocardial protective effects (43), probably
related to its ability to alter cyclic nucleotide levels and
calcium flux (44). The absence of signifi cant beneficial ef-
fects of nitroprusside in myocardial ischemia or even a pos-
sible deterioration (45-47) may relate to its inability to
potentiate prostacyclinrelease. However, reduction in plate-
let aggregation and thromboxane A2 generation may be im-
portant mechanisms of action of nitroprusside in conditions
of increased vascular resistance (10,35).
We thank Susan Ternet Teets tor her assistance in the preparation of this
manuscript
References
Schultz KD. Schultz K. Schultz G Sodium nitroprusside and other
smooth muscle relaxants increase cyclic CMP levels in rat ductus
deferens. Nature 1977.265 750-1
2. Jams RA, Diamond J Relationship between cyclic nucleotide levels
and drug-induced relaxation of smooth muscle. J Pharrnacol Exp Ther
1979.211:480- 4
3 lgnarro LJ. Lippton H. Edwards JC. et al Mechanism of vascular
smooth muscle relaxanon by organic rntrates. nitroprusside and nitric
OXide' evidence for the involvement of Svrutrosothiol as active inter-
medratcs J Pharmacol Exp Ther 1981:21X739-49.
4. Moncada S. Vane JR Arachidonic acid mctabohtes and the mteraction
between platelets and blood vessel wall- N Engl J Med 1979:300:
11 42- 7
5 Needleman P. Kaley G Cardiac and coronary prostaglandin synthesis
and function. N Engl J Med 1978.29X.1122- X.
6 Mehta J. Mehta P Role of blood platelets and prostaglandins in coro-
nary artery disease Am J Cardrol 1981.4X366-73.
7 Needleman P. Wyche A. Raz A Platelet and blood vessel arachrdonate
metabolism and interaction. J Chn lnvevt 1979:63'245-9
8 Lewy RI. Wiener L. Wahnsky P. Lefor AM. Sliver MJ. Smith JB.
Thromboxane release dunng pacmg-mduccd angina pectoris. Possible
vavoconstnctor influence on the coronary vasculature Circulation
19XO.61.116 3- 71.
9 Hrrvh I'D. Hillis LD. Campbell WB. Firth Be. Wrllerson JT Release
of prostaglandms and thromboxane mto the coronary Circulation In
pancnt-, With rschemic heart disease N Engl J Med 1981.304.6X5-
9 1
10 Mehta 1. Mehta P Platelet function studic-, In heart drsease. VI
Enhanced platelet aggregate formation activuy In congesuve heart
tailurc. inhibition by sodium nnroprusvrde Circulanon 1979.60:497-
503
II Mehta J. Mehta P Platelet function m hypertension and effect of
therapy Am J Cardrol 19XI.47 33 1- 4
12 Poplawski A. Skorulvka M. Nrewiarowski S. Increased platelet ad-
he-rveness in hypertenvrve cardiovascular disease J Atherosclcr Res
196X:X 721- 3
13. Levin RE. Jaffe EA. Wehler HB . Tack-Goldman K. Nuroglycenn
stimulates synthesis of prostacyclm by cultured human endothelial
celh J Clm Invest 19XI :67:762-9
14 Levin RI. Weksler HH . Jaffe EA The interaction of sodium rutro-
prussrdc With human endothelial cells and platelets: nitroprusside and
prostacychn synergrstically mhibu platelet function. Circulation
19X2 :66 1299- 307
15 D'Angelo V. Villa S Myvhwrec M. Donau MB. deGaetano G. De-
fective tibnnolyuc and prostacychn-likc activity In human athero-
matous plaque, Thromb Hacmost 197X:39:535-6
630 MEHTA ET AL
NITROGLYCERIN, NITROPRUSSIDE ANDPROSTACYCLIN
l ACC Vol 2. No. 4
October 1983 625-30
16. Kent RS, Kitchell BB, Shand DG, Whorton AR. The ability of vas-
cular tissue to produce prostacyclin decreases with age. Prostaglandins
1981,21:483-90.
17. Mehta J, Roberts A. Human vascular tissues produce thromboxane as
well as prostacyclin. Am J Physiol 1983;244:R839-400.
18 Mehta 1', Mehta J, Crews F, Roy L, Ostrowski N, Horalek C. Com-
parison of umbilical vein models for measurement of relative pros-
tacyclin and thromboxane production. Prostaglandins 1982;24:743-
50.
19. Parry MJ, Randall Ml , Tyler HM, Myhre E, Dale J, Thaulow E.
Selective inhibition of thromboxane synthesis by dazoxiben Increases
prostacyclin production by leukocytes in angina patients and healthy
volunteers. (letter) Lancet 1982;2:164.
20. Smith lB, Jubiz W. OKY 1581: a selective mhibitor of thromboxane
synthesis in vivo and in vitro. Prostaglandins 1981;22:353-62.
2I. Mehta J, Mehta P. Dipyridamole and aspirin in relation to platelet
aggregation and vessel wall prostaglandin generation. J Cardiovasc
Pharmacol 1982;4:688-93.
22. l affe E, Nachman R, Becker C, Minick CR. Culture of human cells
denved from umbilical veins. Identification by morphologic and Im-
munologic criteria. 1 Clin Invest 1973;52:2745-56.
23. Armstrong PW, Armstrong l A, Marks GS. PharmacokInetic-hemo-
dynamic studies of Intravenous nitroglycerin in congestive cardiac
failure. Circulation 1980;62:160-6.
24. Moncada S, Higgs EA, Vane lR . Human arterial and venous tissues
generate prostacyclin (prostaglandin X), a potent inhibitor of platelet
aggregation. Lancet 1977;I :18-23.
25. Pace-Asciak CR, Carrara MC, Rangaraj G, Nicolaou Ke. Enhanced
formation of PGh, a potent hypotensive agent, by aortic rings and
hemogenates of the spontaneously hypertensive rat. Prostaglandins
1978;15:1005- 12.
26. Buchanan MR, Dejana E, Cazenave 11', Mustard JF, Hirsh J Un-
controlled PGh production by whole vessel wall segments due to
thrombin generation In VIVO and It S prevention by heparin. Thromb
Res 1979;16:551-9.
27. Silberbaurer K, Sinzinger H, Winter M. Prostacyclin production by
vascular smooth muscle cells. Lancet 1978;I:1356- 7.
28. Mehta 1', Mehta 1, Hay D. Thromboxane and prostacyclin generation
by Intact human vessels in response 10 balloon catheter trauma Pros-
taglandins Leukotrienes Med 1982;9:539-48
29. Schror K, Grodzrnska L, Darins H. Stimulation of coronary vascular
prostacyclin and inhibition of human platelet thromboxane A2 after
low-dose nitroglycenn . Thromb Res 1981;23.59- 67.
30. Morcillio E, Reid PR, Dubin H, Ghadgaonkar R, Pitt B. Myocardial
prostaglandin E release by mtroglyccnn and modification by indo-
methacin. Am 1 Cardiol 1980;45:53-7.
31. Neichi T, Tomisawa S, Kubodera N, Uchida Y. Enhancementof PGh
formation by a new vasodilator, 2-nicolinamldoethylnItrate in the cou-
pled system of platelets and aortic rmcrosorncs. Prostaglandins
1980;19:577- 86.
32. Forster W. Significance of prostaglandins and thromboxane A2 for the
mode of action of cardiovascular drugs. In: Samuelsson B, Ramwell
PW, Paoletti R, cds. Advances in Prostaglandin and Thromboxane
Research. ed 7. New York: Raven, 1980:609-1 8.
33. Walhs J, Moses lW , Borer IS , Goldberg HL, et al. Nitroglycerin
Increases coronary blood prostacychn levels Incoronary artery disease
(abstr). Circulation 1982;66(suppl (1 ):11- 264.
34. Baumgartner HR Effects of sodium nitroprusside on platelet adhesion,
subsequent aggregation and vasoconstriction (abstr). Thromb Haemost
1977;38:156.
35. Mehta J, Mehta P. Comparative effects of nitroprusside and nitrogly-
cerin on platelet aggregation Inpatients with heart failure J Cardiovasc
Pharmacol 1980:2:25- 33.
36. Schafer AI, Alexander RW, Handin RI Inhibition of platelet function
by organic nitrate vasodilators. Blood 1980;55:649-54 .
37. Mehta J, Mehta 1', Feldman RL, Conti CR. Modulation of vasoactive
prostaglandins by nitroglycerin (abstr) Circulation 1982;66(suppl 11):11-
59.
38. Vatner SF, Higgins CG, Millard RW, Franklin D. Direct and reflex
effects of mtroglycenn on coronary and left ventricular dynamics in
conscious dogs. J Cltn Invest 1972;51:2872- 82.
39. Hood WI' , Amende I, Simon R, Lichtlen PRoThe effects of intra-
coronary nitroglycerinon left ventncular systolic and diastolic function
In man. Circulation 1980;61:I098- 104.
40. Oliva PB, Breckinridge JC. Artenographrc evidence of coronary ar-
terial spasm in acute myocardial Infarction. Circulation 1977;56:366-
74
41. Swain JL, Parker JP, McHale PA, Greenfield JC Jr. Effects of nitro-
glycerin and propranolol on the distribution of transmural myocardial
blood flow during ischemia in the absence of hemodynamic changes
in the unanesthesized dog. J Clin Invest 1979;63:947-5 3.
42. Mehta J, Pepine CJ. Effect of sublingual nitroglycerin on regional
coronary flow in patients with and without coronary disease. Circu-
lation 1978;58.803-7.
43. Lefer AM, Ogletree ML, Smith lB, et al. Prostacyclin: a potentially
valuable agent for preserving myocardial tissue In acute myocardial
ischemia. Science 1978;200'52-4
44. Kukovetz WR, Holzmann S, Wurm A, Poch G. Prostacyclin Increases
cAMP in coronary arteries. J Cyclic Nucleotide Res 1979,5.469-76.
45. Cohn IN, Burke LP. Nitroprussrde Ann Intern Med 1979,91:752-7 .
46. Durrer 10 , Lie KI, Van Capelle FJL, Durrer D. Effect of sodium
rntroprussidc on mortality in acute myocardial Infarction. N Engl J
Med 1982,306:1121- 8.
47. Cohn IN, Franciosa JA, FranCIS CS. Effect of short-term infusion of
sodium nitroprusside on mortality rate in acute myocardial infarction
complicated by left ventricular failure. N Engl J Med 1982;306.
11 29- 35.
